Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with relapsed or refractory disease who had ...
April 29, 2026 11:28 AM EDT News Briefing Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue ENDPOINTS Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that